Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.37 |
| ▸ | ICMT | O60725 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19196920 | 0.94 | CYP2A6 (0.36) | HRH3PTGS1PTGS2FFAR4FFAR1 | |
| SCHEMBL19197050 | 0.92 | CYP2A6 (0.36) | HRH3PTGS1PTGS2NOS3NOS1 | |
| SCHEMBL18503375 | 0.87 | CYP1A2 (0.38) | HRH3PTGS1PTGS2CYP17A1 | |
| SCHEMBL12993151 | 0.82 | TAAR1 (0.42) | HRH3PTGS1PTGS2 | |
| SCHEMBL19197803 | 0.82 | ESR1 (0.36) | HRH3PTGS1PTGS2BACE1FFAR4 | |
| SCHEMBL20373892 | 0.80 | TAAR1 (0.39) | PTGS1PTGS2 | |
| SCHEMBL19197804 | 0.79 | CYP2A6 (0.37) | HRH3PTGS1PTGS2BACE1FFAR4 | |
| SCHEMBL18901756 | 0.77 | TAAR1 (0.39) | PTGS1PTGS2FFAR4FFAR1 | |
| SCHEMBL10301936 | 0.76 | RARB (0.40) | PTGS1PTGS2NOS3NOS1CYP17A1 | |
| SCHEMBL19196919 | 0.76 | CYP2A6 (0.37) | PTGS1PTGS2BACE1FFAR4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180030346-A1 | NEMATIC LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT MANUFACTURED USING SAME | DIC CORPORATION (JP) | 2018-02-01 | — | — | US | disclosed |
| US-20170218271-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE USING THE SAME | DIC CORPORATION (JP) | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030346-A1 | NEMATIC LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT MANUFACTURED USING SAME | LBR, VSIR, KIF23 | HRH3 1497/4885ICMT 3661/4885PTGS1 4434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.